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A 6-year-old girl underwent ureterocystoneostomy (UCN) because of left ﬂank pain due to delayed onset
of ureteral stenosis one and a half years after endoscopic dextranomer/hyaluronic acid copolymer
(Deﬂux) injection for the treatment of vesicoureteral reﬂux (VUR). Histopathological examination indi-
cated chronic inﬂammation with abundant eosinophils characteristic of a reaction to Deﬂux. Several
autoimmune diseases developed during the treatment for ureteral stenosis. First, 2 weeks prior to the
onset of left ﬂank pain, she was diagnosed as having systemic lupus erythematosus. Finally, she died of
pulmonary hemorrhage due to thrombotic thrombocytopenic purpura 4 months after UCN. The fatal
outcome in this case was suspected to be caused by autoimmune syndrome induced by adjuvants, which
in this case was the hyaluronic acid polymer injected into the ureteric oriﬁce for the treatment of VUR.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Dextranomer/hyaluronic acid copolymer (Deﬂux) injection is a
minimally invasive procedure for the treatment of vesicoureteral
reﬂux (VUR) [1], and some reports on the treatment of primary VUR
withDeﬂux injectiondescribed cure rates of approximately 85% after
a single injection [2]. This procedure was adopted by the Ministry of
Health and Labor and was covered by insurance in Japan from 2010,
achieving excellent outcome comparable to those in other countries.
A ureteral obstruction that develops in 0.6e0.7% of patients after
Deﬂux injection, typically occurs in the early postoperative period
[1,3e5]. We encountered a female patient who developed delayed
onset of ureteral stenosis after repeated Deﬂux injection simulta-
neously developed autoimmune disease, and she died of pulmonary
hemorrhage due to thrombotic thrombocytopenic purpura. Since
this case is compatible with a new concept “Autoimmune inﬂam-
matory syndrome induced by adjuvants (ASIA)”, a possible correla-
tion between and autoimmune diseases is discussed.1. Case report
A 6-year-old girl was transferred to our institution because of
repeated episodes of febrile urinary tract infection (UTI). A voidingSurgery, Ibaraki Children’s
pan. Tel.: þ81 29 254 1151;
Inc. This is an open access article ucystourethrogramdemonstrated bilateral VURof grade 2. Endoscopic
injection of Deﬂux was administered to treat VUR (volume of injec-
tion: 0.4mL, left and right). However, left VURof grade 2 persisted for
3months. A second injection of Deﬂux (0.4mL) for left VURwas then
administered, afterwhich she remainedwell for 18months,when she
presented with left ﬂank pain. Ultrasonography showed left hydro-
nephrosis and hydroureter along with a bulky lesion around the left
ureteric oriﬁce (Fig. 1a). Mercaptoacetyltriglycine 3 scintigraphy
showed partial obstruction of the left ureteric oriﬁce. Cystoscopy
demonstrated that the mucosa around the left ureteric oriﬁce was
bulky and swollen. A ureteric stent was placed during cystoscopy in
the left ureter through the stenotic oriﬁce (Fig. 1b).
Two weeks prior to the onset of left ﬂank pain, she complained
of swelling and pain in the cervical lymph nodes, erythema on both
cheeks, and Raynaud phenomenon. Laboratory test results,
including positive antinuclear antibody (speckled pattern, titer
1:1280) and low hemolytic activity at 18.9 U/mL measured by 50%
hemolytic unit of complement (CH50), were all compatible with
systemic lupus erythematosus. We considered the pre-existing
autoimmune disease to have caused stenosis of the left ureteric
oriﬁce. Thus, we performed ureterocystoneostomy (UCN) on both
sides 2 months after ureteric stent placement, considering the risk
of a similar stenosis at the right ureteric oriﬁce. Histopathological
examination of the resected specimen of the left stenotic ureter
showed granulation tissue, giant cell hyperplasia and abundant
inﬁltration of eosinophils and lymphocytes (Fig. 2a, b).nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. a) Ultrasonography shows the bulky lesion around the left ureteric oriﬁce (arrow). b) Cystoscopy shows the bulky and swollen mucosa around the left ureteric oriﬁce.
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obstruction or UTI. At that time, however, she was diagnosed as
having Evans syndrome, a combination of autoimmune hemolytic
anemia and idiopathic thrombocytopenic purpura. In spite of
treatment with steroid and gamma-globulin, she developed
thrombotic thrombocytopenic purpura (TTP), which led to fatal
pulmonary hemorrhage 4 months after UCN. Autopsy showed
extensive alveolar hemorrhage and systemic platelet thrombosis in
the peripheral arteries. No recurrence of stenosis in the urinary
tract system was noted.
2. Discussion
The case reported here raises the concern of whether repeated
hyaluronic acid injection inﬂuenced the development of autoim-
mune diseases. Autoimmune inﬂammatory syndrome induced by
adjuvants (ASIA) is a new concept ﬁrst reported in 2011. According
to this concept, systemic inﬂammation and autoimmune diseases
may develop with delayed onset following exposure to biomaterial
used in plastic surgery, such as silicone in breast implants [6]. Hy-
aluronic acid was also identiﬁed as such a biomaterial [7]. The ASIA
diagnostic criteria include repeated injection and identiﬁcation of
biomaterial substance, positive laboratory tests, local chronic
inﬂammation, systemic symptoms (i.e., fever, fatigue, vasculitis,
Raynaud phenomenon, joint pain, lymphadenopathy with pain),
development of autoimmune disease (including collagen disease),
relief of local inﬂammation by the removal of the biomaterial, and
presence of speciﬁc HLA (i.e. DR81, DQ81) [6]. The risk factors forFig. 2. a) Histopathological examination of the resected specimen of the left stenotic ureter
acid copolymer (arrowheads). b) Inﬁltration of eosinophils and lymphocytes is seen.ASIA include history of autoimmune reaction to bioimplant; history
of autoimmune disease; allergic constitution and history of atopy;
and hereditary factors or family history for autoimmunity [8]. Our
case ﬁndings were compatible with the criteria and risk factors for
ASIA. Therefore, we assumed that her series of autoimmune re-
actions were triggered by Deﬂux injection, even though this auto-
immune reaction due to hyaluronic acid is an extremely rare
condition. Pulmonary hemorrhage is often a fatal complication in
TTP, which occurred in this case.
Bulky and swollen ureteric oriﬁce seen on histopathological
examination is a chronic inﬂammatory reaction to hyaluronic acid,
which is compatible with ASIA and also delayed onset ureteral
stenosis [1,4,9e12]. The ﬁndings of ASIA shown by Reig et al. [7],
which included granulation tissue giant cell hyperplasia, macro-
phages, and inﬁltration of B and T cell lymphocytes, are in agree-
ment with our ﬁndings of immunoreactivity in the biopsy
specimen.
After UCN, we assumed that the autoimmune reaction to Deﬂux
injection triggered stenosis of the left ureteric oriﬁce and chronic
inﬂammation. However, we found that our case ﬁndings are com-
parable to those indicative of ASIA. Therefore, the risks of delayed
systemic inﬂammatory reaction development and autoimmune
disease should be considered after injection of Deﬂux, especially in
cases of repeated procedures. Moreover, Deﬂux injection for VUR
should be carefully used in patients with a history of autoimmune
disease, although such conditions are limited to the pediatric
population. Adequate understanding about development of ASIA is
necessary for patients with an allergic constitution or a familyshows granulation tissue, giant cell hyperplasia (arrow) and component of hyaluronic
K. Suda et al. / J Ped Surg Case Reports 4 (2016) 10e1212history of autoimmune disease when Deﬂux injection is indicated.
We suggest that hyaluronic acid be removed immediately to stop
continuous inﬂammation and development of ASIA if ureteral ste-
nosis or obstruction occurs.
3. Conclusion
We report a case of ASIA associated with a continuous chronic
inﬂammation of the left ureteric oriﬁce caused by repeated Deﬂux
injections. We recommend to carefully assess a medical history of
an allergic constitution or a family history of an autoimmune dis-
ease when to repeat the Deﬂux injection.
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